Thematics Asset Management Has $4.92 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Thematics Asset Management grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 26.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,572 shares of the medical research company’s stock after buying an additional 18,451 shares during the quarter. Thematics Asset Management’s holdings in Exact Sciences were worth $4,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in EXAS. Perigon Wealth Management LLC grew its position in Exact Sciences by 3.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after acquiring an additional 264 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Exact Sciences by 2.0% during the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock valued at $763,000 after buying an additional 269 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Exact Sciences by 2.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock worth $812,000 after buying an additional 300 shares during the last quarter. Curi RMB Capital LLC boosted its stake in shares of Exact Sciences by 1.7% during the 4th quarter. Curi RMB Capital LLC now owns 24,896 shares of the medical research company’s stock worth $1,399,000 after acquiring an additional 428 shares in the last quarter. Finally, Patten & Patten Inc. TN increased its holdings in shares of Exact Sciences by 1.8% during the 4th quarter. Patten & Patten Inc. TN now owns 26,153 shares of the medical research company’s stock valued at $1,470,000 after acquiring an additional 460 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Down 1.6 %

Shares of EXAS opened at $41.58 on Friday. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a 50-day moving average price of $45.87 and a two-hundred day moving average price of $54.95. The stock has a market cap of $7.72 billion, a price-to-earnings ratio of -7.46 and a beta of 1.14. Exact Sciences Co. has a 12 month low of $39.97 and a 12 month high of $72.83.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EXAS has been the subject of a number of recent analyst reports. Bank of America decreased their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Scotiabank boosted their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Piper Sandler decreased their target price on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, Barclays cut their price target on Exact Sciences from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.25.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.